For example, correcting pathogenic mutations like those in the MYH6 gene associated with hypertrophic cardiomyopathy necessitates efficient delivery of gene editing agents specifically to cardiac muscle cells, enabling restoration of normal myocardial function [47]. This evidence concerns the gene MYH6 and hypertrophic cardiomyopathy.